Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of analytical accuracy of HER2 status in patients with breast cancer

29 Aug 2020

Abstract excerpt

Human epidermal growth factor receptor 2 (HER2) gene status and overexpression, occurring in ~ 13.6% of primary breast cancers, is essential for identifying patients likely to benefit from biological treatment. In this method of evaluation study, we tested and compared the HER2 gene-protein assay (GPA) with routine HER2 immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The GPA was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Biosensing Techniques and Applications
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32860265
DOI: 10.1111/apm.13076

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of analytical accuracy of HER2 status in patients with breast cancerPMID 32860265Read ↗

Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancerSemantic proximity Read ↗

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerSemantic proximity Read ↗

The assessment of HER2 status in breast cancer: the past, the present, and the futureSemantic proximity Read ↗

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic ConsiderationsSemantic proximity Read ↗

Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation PracticeSemantic proximity Read ↗

HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ HybridizationSemantic proximity Read ↗

Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity Read ↗

Gastric HER2 Testing Study (GaTHER)Semantic proximity Read ↗

Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancersSemantic proximity Read ↗

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American PathologistsSemantic proximity Read ↗

Single HER2-Positive Tumor Cells are Detected in Initially HER2-Negative Breast Carcinomas using the DEPArray™–HER2-FISH WorkflowSemantic proximity Read ↗

Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic StudiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.